19 results
The properties of CBD, namely potential effects on variables pertaining to fear extinction and potentially on fear retention/reinstatement while having non of the problematic side-effects found in Δ9-THC, make CBD plausibly preferential over Δ9-THC…
Primary objective: To evaluate the efficacy of GWP42003-P as adjunctive treatment inreducing the number of drop seizures when compared with placebo, inpatients with LGS.Drop seizure is defined as an attack or spell (atonic, tonic or tonic-clonic)…
The purpose of the study is to investigate the effect of CBD on specific ECG parameters. Importantly, it will be evaluated if there is a prolongation of the QT interval. When the QT interval is prolonged, repolarization of the heart is delayed. This…
The primary objective of this study is to compare microglia activation as measured with proton Magnetic Resonance Spectroscopy (1H-MRS) between recent-onset schizophrenia patients who are randomised to CBD and those randomised to placebo. Secondary…
The properties of CBD, namely potential effects on variables pertaining to fear extinction and potentially on fear retention/reinstatement while having non of the problematic side-effects found in *9-THC, make CBD plausibly preferential over *9-THC…
Primary Objective Blinded Phase:• To evaluate the efficacy of GWP42003-P as add-on therapy in reducing the frequency of seizures when compared with placebo in patients with TSC.Open-label Extension:• To evaluate via the adverse events (AE) profile…
To evaluate the long term safety and tolerability of GWP42003-P, as adjunctive treatment, in children and adults with inadequately controlled DS or LGS.All Patients:To evaluate the effect of GWP42003-P, as adjunctive treatment, on:* Quality of life…
The aim of this research project is to investigate cannabidiol as a new medicine to target the cannabinoid system in the reduction of anxiety disorder symptoms. The research question is whether cannabidiol, as an augmentation strategy of exposure…
To assess the efficacy of GWP42003-P as an adjunctive antiepileptic treatment compared with placebo, with respect to the percentage change from baseline during the treatment period of the study in convulsive seizure frequency. The dose response…
The purpose of the study is to investigate to what extent CBD is safe and tolerated. It will also be investigated how quickly and to what extent CBD is absorbed and eliminated from the body (this is called pharmacokinetics). Furthermore the effect…
To investigate the effect of a three-week treatment with cannabidiol (CBD) on anxiety in patients with a primary brain tumor that have no active oncological treatment. Depression, fatigue and general quality of life are secondary outcome measures.…
Primary Objective: To determine whether GWP42003-P affects the pharmacokinetic (PK) profile of stiripentol (STP) or valproate (VPA).Secondary Objective: To assess the safety and tolerability of GWP42003-P in the presence of STP or VPA.To assess…
The purpose of this study is to separately evaluate 2 agents with different mechanisms of action that may be effective in subjects with low-risker MDS. The design of this study will allow an unbiased assessment of which agent, if either, will…
Primary:- To investigate the modulatory effect profile of single doses of oral CBD on THC-induced effects in healthy volunteers.Secondary:- To assess the analgesic effect of a single dose of THC in healthy volunteers measured with the PainCart test…
The aim of this project is to investigate CBD as a new medicine to target the ECS in the reduction of anxiety symptoms. Subsidiary aims of the project are to investigate the effects of CBD on fear extinction and extinction consolidation, stress…
• To assess effects of a single oral dose of 160 and 1500 mg cannabidiol compared to placebo on a specific set of pain modalities• To assess effects of a single oral dose of 160 and 1500 mg cannabidiol compared to placebo on UVB- and capsaicin-…
To study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
The primary objective is to demonstrate the superiority of ziltivekimab 15 mg s.c. once-monthly in reducing the risk of MACE (as defined by the primary endpoint) compared to placebo, both added to standard of care, in participants with established…
In this study we will look at the blood levels of the study compound ziltivekimab. We will investigate how quickly and to what extent different compositions of ziltivekimab are absorbed, transported, and eliminated from the body. Ziltivekimab is not…